Inj ustekinumab-srlf, 1 mg
Products billed under this code include Imuldosa.
Payment limit per 1 MG, by effective quarter, 3Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under Q5098
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Imuldosa | Accord BioPharma, Inc | 69448-0017-63 | 45 | $417.15 |
| Imuldosa | Accord BioPharma, Inc | 69448-0018-63 | 90 | $834.30 |
| Imuldosa | Accord BioPharma, Inc | 69448-0019-26 | 130 | $1,205.10 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $9.27 | −$2.281 | 1 MG | Inj ustekinumab-srlf, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $11.551 | – | 1 MG | Inj ustekinumab-srlf, 1 mg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026